Hepatitis C – A Nasty Liver Virus
- Home
- Hepatitis C – A Nasty Liver Virus
It is estimated that 170 million people worldwide are infected with the hepatitis C virus.
This month of March 2021, is the five-year anniversary of the introduction of curative drug treatments for the hepatitis C virus. These drugs known as direct-acting antivirals, have changed the course of history for hepatitis C sufferers bringing tremendous physical and emotional relief. We have come a long way with these drugs providing a 95% cure rate, but we cannot afford to get complacent.
It is vital that people are aware of the way hepatitis C can be transmitted, how easy it is to be tested for infection, and the importance to get early treatment.
Treatment with direct-acting antiviral drugs is effective and safe and results in viral clearance from the body (known as a sustained virological response [SVR]) in the vast majority of patients. A SVR usually lasts a lifetime and produces a reduction of hepatitis C related liver diseases and risk of death. However, it is good not to get complacent, as after treatment with these drugs some patients may still have a major risk of progressive liver damage; this can lead to liver cirrhosis, liver failure and liver (hepatocellular) cancer. This is the result of ongoing chronic inflammation in the liver.
Take natural anti-inflammatories for the liver such as Livatone Plus which contains Milk Thistle, selenium, activated B vitamins, antioxidants and N-Acetyl-Cysteine (NAC). It is recommended to take extra NAC twice daily. Livatone Plus is the most comprehensive liver formula available and has been tested in a clinical study of patients with liver inflammation caused by fatty liver.
References
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Nahon P, et al, Gastroenterology. 2017 Jan;152(1):142-156.e2. doi: 10.1053/j.gastro.2016.09.009. Epub 2016 Sep 15.PMID: 27641509
Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. Tmu N, et. Al, J Clin Exp Hepatol. 2019 Jan-Feb;9(1):4-12. doi: 10.1016/j.jceh.2018.02.009. Epub 2018 Mar 6.PMID: 30765933
American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Jacobson IM, et. Al, Gastroenterology. 2017 May;152(6):1578-1587. doi: 10.1053/j.gastro.2017.03.018. Epub 2017 Mar 23.PMID: 28344022 Review.
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Morgan TR, et. Al, HALT-C Trial Group. Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744.PMID: 20564351
Direct-acting antivirals for chronic hepatitis C. Jakobsen JC, et. Al, Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143.
The above statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
}
When you submit your email, you agree to join our mailing list and receive helpful updates, special offers, and product news.